Moderna shares plunge over 25% despite announcement of cancer vaccine Phase 3 results
MRNA Moderna Inc
$199.33 +1.29%
View chart & analysis → - 1Moderna's melanoma vaccine recorded a 42% reduction in the risk of recurrence or death when used in combination with Keytruda compared to Keytruda monotherapy in Phase 3.
- 2Moderna shares fell by more than 25% during the October 22 session.
- 3Among pancreatic cancer research patients, 55% remained without recurrence at the 17-month mark.
So what's the key point?
Results showed that Moderna's cancer vaccine reduced the risk of recurrence or death by 42%. However, despite this news, Moderna's stock price fell by more than 25%.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.